BRIEF-Beigene announces first patient dosing in China phase I trial with investigational anti-pd-1 monoclonal antibody bgb-a317

* Beigene ltd- dosing of first patient in phase i clinical

trial of bgb-a317 in mainland chinese patients with advanced

solid tumors

Read more